2.88
4.32%
-0.13
Precedente Chiudi:
$3.01
Aprire:
$2.922
Volume 24 ore:
4,000
Relative Volume:
0.19
Capitalizzazione di mercato:
$15.89M
Reddito:
-
Utile/perdita netta:
$-14.29M
Rapporto P/E:
-0.5208
EPS:
-5.53
Flusso di cassa netto:
$-12.27M
1 W Prestazione:
-14.03%
1M Prestazione:
-33.02%
6M Prestazione:
-43.49%
1 anno Prestazione:
-23.20%
Aprea Therapeutics Inc Stock (APRE) Company Profile
Nome
Aprea Therapeutics Inc
Settore
Industria
Telefono
617-463-9385
Indirizzo
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Confronta APRE con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
APRE | 2.9228 | 15.89M | 0 | -14.29M | -12.27M | -5.53 |
VRTX | 449.90 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 745.15 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 595.64 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 246.18 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 108.10 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2020-12-28 | Downgrade | Robert W. Baird | Outperform → Neutral |
2020-12-16 | Iniziato | Berenberg | Buy |
2020-09-29 | Ripresa | JP Morgan | Neutral |
2020-06-22 | Iniziato | H.C. Wainwright | Neutral |
2020-04-21 | Iniziato | Robert W. Baird | Outperform |
2019-10-28 | Iniziato | JP Morgan | Neutral |
2019-10-28 | Iniziato | Morgan Stanley | Equal-Weight |
2019-10-28 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aprea Therapeutics Inc Borsa (APRE) Ultime notizie
HC Wainwright Has Bullish Outlook for APRE FY2024 Earnings - Defense World
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher - MSN
Aprea Therapeutics Reports Q3 Financials and Advances in Clinical Trials - MSN
HC Wainwright Reaffirms Buy Rating for Aprea Therapeutics (NASDAQ:APRE) - Defense World
Aprea Therapeutics (NASDAQ: APRE) Announces Financial Results and Corporate Updates - Defense World
Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Health Catalyst signs definitive agreement to acquire Intraprise Health - MSN
Aprea Therapeutics Inc (APRE) Quarterly 10-Q Report - Quartz
Aprea Therapeutics Inc (APRE) Q3 2024 Earnings: Revenue Hits $0. - GuruFocus.com
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MyChesCo
Aprea Therapeutics Presents Promising Safety Data for WEE1 Inhibitor at International Symposium - MSN
DDR Defective Tumors Market Growth Surge: Key Players and Market - openPR
Can Aprea Therapeutics (APRE) Spring Back This Year? - RTTNews
Aprea Therapeutics (NASDAQ:APRE) Rating Reiterated by HC Wainwright - Defense World
Aprea therapeutics director sells shares worth $29,583 By Investing.com - Investing.com South Africa
Aprea therapeutics director sells shares worth $29,583 - Investing.com India
Aprea therapeutics CEO Gilad Oren buys $1,957 in stock - Investing.com
Aprea Therapeutics presents preliminary results on APR-1051 - Yahoo Finance
Aprea therapeutics CEO Gilad Oren buys $1,957 in stock By Investing.com - Investing.com UK
Insider Spends US$132k Buying More Shares In Aprea Therapeutics - Yahoo Finance
Aprea Therapeutics falls on data from APR-1051 study in cancer-associated gene alterations - Seeking Alpha
Aprea reports safe trial results for new cancer drug - Investing.com
Aprea reports safe trial results for new cancer drug By Investing.com - Investing.com UK
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - The Manila Times
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR - EIN News
Positive Signs As Multiple Insiders Buy Aprea Therapeutics Stock - Simply Wall St
Aprea therapeutics director Duey Marc acquires $131,700 in stock By Investing.com - Investing.com South Africa
Aprea therapeutics director Duey Marc acquires $131,700 in stock - Investing.com India
Aprea Therapeutics CEO Gilad Oren buys $725 in common stock By Investing.com - Investing.com South Africa
Aprea therapeutics CFO John Hamill acquires shares worth $123 - Investing.com
Aprea Therapeutics CEO Gilad Oren buys $725 in common stock - Investing.com India
Aprea Therapeutics director Duey Marc buys $490 in stock - Investing.com
Aprea therapeutics CFO John Hamill acquires shares worth $123 By Investing.com - Investing.com South Africa
Aprea Therapeutics director Duey Marc buys $490 in stock By Investing.com - Investing.com South Africa
Novavax’s stock slides 19% after FDA puts clinical hold on COVID and flu vaccine candidates - MSN
Aprea therapeutics director Bernd Seizinger buys $26,800 in stock By Investing.com - Investing.com Australia
Aprea Therapeutics president Gilad Oren buys $2,971 in stock - Investing.com India
Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit - MyChesCo
Aprea therapeutics CFO John Hamill buys $1,174 in common stock By Investing.com - Investing.com South Africa
Aprea therapeutics director Bernd Seizinger buys $26,800 in stock - Investing.com India
Aprea Therapeutics president Gilad Oren buys $2,971 in stock By Investing.com - Investing.com Canada
Aprea Therapeutics Inc Azioni (APRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):